Tudor Investment Corp Et Al Trims Stock Position in USANA Health Sciences, Inc. (NYSE:USNA)

Tudor Investment Corp Et Al decreased its position in USANA Health Sciences, Inc. (NYSE:USNA – Get Rating) by 45.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,019 shares of the company’s stock after selling 8,208 shares during the quarter. Tudor Investment Corp Et Al owned 0.05% of USANA Health Sciences worth $562,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Covestor Ltd raised its position in USANA Health Sciences by 92.7% in the first quarter. Covestor Ltd now owns 927 shares of the company’s stock valued at $74,000 after purchasing an additional 446 shares during the period. Quadrant Capital Group LLC raised its position in USANA Health Sciences by 318.1% in the third quarter. Quadrant Capital Group LLC now owns 949 shares of the company’s stock valued at $53,000 after purchasing an additional 722 shares during the period. Point72 Hong Kong Ltd purchased a new stake in USANA Health Sciences in the second quarter valued at approximately $69,000. Captrust Financial Advisors raised its position in USANA Health Sciences by 104.6% in the second quarter. Captrust Financial Advisors now owns 1,103 shares of the company’s stock valued at $80,000 after purchasing an additional 564 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in USANA Health Sciences by 290.0% in the third quarter. Tower Research Capital LLC TRC now owns 1,595 shares of the company’s stock valued at $89,000 after purchasing an additional 1,186 shares during the period. Hedge funds and other institutional investors own 52.62% of the company’s stock.

USANA Health Sciences Trading Down 3.2 %

USANA Health Sciences stock opened at $61.42 on Tuesday. USANA Health Sciences, Inc. has a twelve month low of $48.61 and a twelve month high of $88.54. The stock’s fifty day simple moving average is $58.49 and its 200-day simple moving average is $57.45. The firm has a market capitalization of $1.18 billion, a P/E ratio of 17.11 and a beta of 0.74.

USANA Health Sciences (NYSE:USNA – Get Rating) last posted its quarterly earnings data on Tuesday, February 7th. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.31. USANA Health Sciences had a return on equity of 16.92% and a net margin of 6.94%. The business had revenue of $227.96 million for the quarter. During the same period in the prior year, the company posted $1.03 EPS. Sell-side analysts predict that USANA Health Sciences, Inc. will post 2.85 earnings per share for the current year.

Insider Transactions at USANA Health Sciences

In related news, CEO Kevin Guest sold 13,288 shares of the business’s stock in a transaction on Wednesday, February 22nd. The shares were sold at an average price of $60.28, for a total transaction of $801,000.64. Following the completion of the transaction, the chief executive officer now owns 9,355 shares in the company, valued at $563,919.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Joshua Foukas sold 3,771 shares of the business’s stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $61.01, for a total transaction of $230,068.71. Following the completion of the transaction, the insider now owns 3,012 shares in the company, valued at $183,762.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin Guest sold 13,288 shares of the business’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $60.28, for a total transaction of $801,000.64. Following the transaction, the chief executive officer now owns 9,355 shares of the company’s stock, valued at approximately $563,919.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 19,335 shares of company stock valued at $1,171,915. 0.36% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on USNA. DA Davidson boosted their target price on USANA Health Sciences from $49.00 to $52.50 and gave the company a “neutral” rating in a research report on Monday, February 13th. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 16th.

USANA Health Sciences Company Profile

(Get Rating)

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm’s brands include Procosa and MagneCal D. The company was founded by Myron W.